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Abstract
Systemic Mastocytosis (SM) is a clonal disease characterized by abnormal accumulation of mast cells in multiple organs.
Clinical presentations of the disease vary widely from indolent to aggressive forms, and to the exceedingly rare mast cell
leukemia. Current treatment of aggressive SM and mast cell leukemia is unsatisfactory. An imatinib-resistant activating
mutation of the receptor tyrosine kinase KIT (KIT D816V) is most frequently present in transformed mast cells and is
associated with all clinical forms of the disease. Thus the etiology of the variable clinical aggressiveness of abnormal mast
cells in SM is unclear. TET2 appears to be mutated in primary human samples in aggressive types of SM, suggesting a
possible role in disease modification. In this report, we demonstrate the cooperation between KIT D816V and loss of
function of TET2 in mast cell transformation and demonstrate a more aggressive phenotype in a murine model of SM when
both mutations are present in progenitor cells. We exploit these findings to validate a combination treatment strategy
targeting the epigenetic deregulation caused by loss of TET2 and the constitutively active KIT receptor for the treatment of
patients with aggressive SM.
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Introduction
Systemic mastocytosis (SM) is a clonal disease of the mast cell
lineage with clinical presentations ranging from mild forms to
more aggressive disease [1]. The current classification of SM
includes 5 subtypes: indolent SM (ISM), smoldering SM (SSM),
SM with an associated hematologic non-mast cell-lineage disease
(SM-AHNMD), aggressive SM (ASM), and mast cell leukemia
(MCL) [2,3]. Most cases of SM are mild and respond to
symptomatic therapy with antihistamines and inhibitors of mast
cell degranulation. Management of aggressive types of disease,
where mast cells infiltrate multiple organs (including skin, lymph
nodes, spleen, liver, lungs, heart and bone marrow) is more
challenging and is approached with chemotherapy or other
targeted therapeutic interventions.
In adults, most cases of SM are associated with the presence of
activating mutations in the receptor tyrosine kinase c-KIT (KIT),
which binds to stem cell factor (SCF or KIT ligand), a known
trophic factor for mast cells.
By far the most frequent KIT mutation in mastocytosis is a
substitution of aspartic acid to valine at position 816 (KIT D816V)
that leads to constitutive activation of the receptor [4,5]. The
presence of the KIT D816V mutation does not appear to correlate
with a specific subtype of the disease and does not contribute to the
disease prognosis. Moreover, this mutation is imatinib-resistant
[6,7] and targeted therapy with second-generation tyrosine kinase
inhibitors (TKIs) has shown variable success [8,9], although
promising preliminary data have been obtained with midostaurin
(PKC412) [10].
Additional cooperating events may contribute to the pathogen-
esis and/or the phenotype of SM [11,12,13]. Mutations in TET2
have been reported in as many as 40% of KIT D816V-positive SM
cases [11,12]. TET2 is an enzyme that catalyzes the conversion of
5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) and
further modified cytosines, regulating gene expression at the
cellular level [14,15]. Loss-of-function mutations in TET2 have
been reported in a variety of hematological malignancies including
acute myeloid leukemias (AMLs), chronic myelomonocytic leuke-
mia (CMML), myeloproliferative neoplasms (MPNs), myelodys-
plastic syndromes (MDS) and lymphoid malignancies [16,17,18].
In mouse models, loss of one or both copies of Tet2 has been
shown to contribute to the pathogenesis of hematological
malignancies by increasing the self-renewal capacity of the
hematopoietic stem cell compartment and expanding the imma-
ture pool of myeloid and lymphoid progenitors [19,20,21].
In SM, the coexistence of mutations in TET2 and the KIT
D816V lesion have recently been suggested to lead to a more
aggressive type of disease and an overall worse prognosis, although
the effect on mast cell biology was not properly analyzed [22]. In
the current study, we investigate the biological relevance of loss of
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both in vivo in a mouse model and in vitro in human cells. We
demonstrate that mutations in both loci cooperate in the mast cell
lineage to cause an aggressive type of mastocytosis. Furthermore,
we show that Tet2 loss-of-function makes KIT D816V-positive
mastocytosis amenable to combination therapy with epigenetic
modifiers and TKIs.
Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
Institutional Animal Care and Use Commitee at Boston
Children’s Hospital approved all of the animal care procedures
and experiments (authorization no. 11-03-1894R).
Mice
Kit D814V
Fl mice have been previously described [23]. The Kit
D814V transgene is expressed upon Cre-mediated excision of the
loxP-flanked transcriptional stop element in adult mice. Tet2
Fl/Fl
mice have been described elsewhere [19]. These mice were
crossed to Kit D814
Fl mice to generate Tet2
Fl/WT;Kit D814V
double transgenic animals, and to Mx1-Cre [24] or Mcpt5-Cre
[25] mice to generate Tet2
Fl/WT;Mx1-Cre and Tet2
Fl/WT;Mcpt5-
Cre double transgenic animals. Tet2
Fl/WT;Kit D814V were then
crossed to Tet2
Fl/WT;Mx1-Cre or Tet2
Fl/WT;Mcpt5-Cre mice and
their progeny were used for subsequent experiments. In mice
carrying the Mx1-Cre allele, Cre expression was induced by 3 i.p.
injections of 250 mg polyinosine-polycytidylic acid (pI:C) every
second day to activate expression of the transgenic Kit D814V and
deletion of one or both Tet2 alleles. Mice were treated with pI:C at
4 weeks of age. All mice used in this study were backcrossed for at
least 5 generation and maintained on a C57/BL6 background. All
mice were housed in the experimental animal facility at Boston
Children’s Hospital and were provided free access to food and
water.
Experimental procedures
For survival studies, starting one week after the last pI:C
injection, mice were monitored every other day to detect early
signs of leukemia. Whenever ruffled fur, reduced movements or
hind limb paralysis were noticed, mice were bled by retro-orbital
bleeding, and humanely euthanized using carbon dioxide,
followed by cervical dislocation. Of the experimental cohorts
reported in leukemia studies, all mice were humanely euthanized
when they met any of the humane endpoints listed above. One
mouse in the primary leukemic mice cohort was lost at follow-up
and found dead before humane euthanasia could be performed.
WBC counts couldn’t be obtained for this animal.
For survival studies and for determination of peripheral blood
chimerism, mice underwent retro-orbital bleeding after anesthesia
with isofluorane. Following this procedure, animals were treated
with eye lubricant to minimize their discomfort.
Cell lines
The human mast cell leukemia cell line HMC-1.2 (carrying the
KIT G560V and the KIT D816V activating mutations) was a kind
gift from Dr. JH Butterfield (Mayo Clinic, Rochester, MN) [26].
HMC-1.2 were grown in RPMI supplemented with 10% fetal
bovine serum (FBS), 2 mM glutamine, 100 U/mL penicillin and
0.1 mg/mL streptomycin in a humidified incubator with 5% CO2
at 37uC. Fresh HMC-1.2 cells were thawed from an original stock
every 8 weeks, and cells were periodically checked for the presence
of metachromatic granules and for expression of the KIT receptor
[27].
Derivation of BMMCs
Bone marrow-derived mast cells (BMMCs) were generated from
low density BM cells by four weeks of culture in RPMI
supplemented with 10% fetal bovine serum (FBS), 2 mM
glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin and
10 ng/mL of mouse recombinant IL-3 (PeproTech, Rocky Hill,
NJ) in a humidified incubator with 5% CO2 at 37uC.
Giemsa staining
Giemsa staining was performed on skin and stomach sections
from diseased animals using standard protocols. Slides were
evaluated by photomicroscopy using the Spot Advance software
from Spot
TM Imaging Solutions, (Sterling Heights, MI) on an
Eclipse E400 microscope from Nikon (Melville, NY). Images were
taken using a 206objective.
Cell proliferation and apoptosis
Apoptosis was evaluated using the Annexin V-APC flow kit
from BD Biosciences (San Jose, CA). Cells were counterstained
with 7-AAD (Invitrogen, Carlsbad, CA). For proliferation assays,
cells were cultured in the presence of 5-bromo-29-deoxy-uridine
(BrdU) for 4 hours then fixed, permeabilized, and stained using
the APC BrdU Flow Kit (BD Biosciences), following the
manufacturer’s instructions. Data were acquired on a LSR II
flow cytometer (BD Biosciences). For cell growth, cells were
plated in 96-well plates at 10,000 cells/well and lysed at the
indicated time point with CellTiter-Glo Luminescent Cell
Viability Assay reagent (Promega, Madison, WI). Luminescence
was read using a DTX 880 plate reader from Beckman Coulter
(Brea, CA). Cell growth was normalized to 5 days post-
transduction.
Statistical analysis
Datasets were compared by two-tailed t tests and P values less
than .05 were considered statistically significant.
Results
Knock down of TET2 increases proliferation of a KIT
D816V positive human mast cell leukemia cell line
To model the cooperation between loss of function of TET2
and the KIT D816V mutation in vitro, we knocked down (KD)
TET2 in a human mast cell leukemia cell line (HMC-1.2)
harboring the KIT D816V mutation. We first documented the
absence of mutations (except for one annotated SNP) in the
coding sequence of TET2 in the HMC-1.2 cell line (data not
shown). In absence of a reliable commercially available antibody
for TET2, we determined the efficiency of five individual KD
vectors by qPCR (Figure S1, panel A). We chose two vectors (sh-1
and sh-3) that achieved an average KD of TET2 of 45% and
34%, respectively (Table S1). As expected, KD of TET2 in
HMC-1.2 cells caused a reduction in the total content of 5-hmC,
an intermediate in the DNA demethylation reaction catalyzed by
TET2 (Figure S1, panel B). In this cell line, silencing of TET2
also caused a significant increase in cellular growth over time
(Fig. 1A) (P=.05 TET2 sh-1 vs. control shRNA [ctr sh], P=.02
TET2 sh-3 vs. ctr sh, at day 12 after transduction). The increase
in cell numbers was associated with increased proliferation upon
silencing of TET2, as assessed by BrdU incorporation (Fig. 1B
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PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e96209and 1C) (% cells in S phase=5.860.5 ctr sh vs. 12.463.3 TET2
sh-1 and 16.6360.9 TET2 sh-3, P=.09 TET2 sh-1 vs. ctr sh,
P=.0007 TET2 sh-3 vs. ctr). To address whether loss of TET2
would modify migratory properties of HMC-1.2 cells, we
compared cells transduced with two shRNAs against TET2 (sh-
1 and sh-3) to a ctr sh. There was no difference in the number of
migrated cells in response to human SCF under all conditions
analyzed (Figure S1, panel C). These data indicate that loss of
function of TET2 cooperates with KIT D816V to increase the
proliferative capacity of human malignant mast cells, without
modifying their migratory properties.
Tet2
2/2;Kit D814V mice develop a more aggressive type
of systemic mastocytosis compared to Tet2
+/+;Kit D814V
animals
Next, we examined the in vivo phenotype caused by simulta-
neous expression of Kit D814V (the mouse homologue of KIT
D816V) and deletion of Tet2 in the hematopoietic compartment of
compound mice. In all genotypes expressing the Kit D814V allele
there was a significant increase in mast cell infiltration of several
organs. In the skin, the average number of mast cells per scored
section was 56.964 in Tet2
+/+;Kit D814V vs. 96.3618.9 in
Tet2
2/2;Kit D814V (n=80 from 4 independent animals/
genotype, P=.04, Fig 2A). In the esophagus/stomach, the average
number of mast cells per scored section was 23.163.6 in Tet2
+/
Figure 1. Increased proliferation of HMC-1.2 cells after knock down of TET2. A) HMC-1.2 cells were treated with two hairpins against TET2
(TET2 sh-1 and TET2 sh-3) or a control shRNA (ctr sh). Cell growth was calculated using the CellTiter-Glo assay from Promega. Data are presented as
fold change relative to day 5 after transduction. Values represent mean 6SEM, n=3 independent experiments. *P,.05. B) Percentage of cells in S-
phase determined by BrdU incorporation in HMC-1.2 cells treated with TET2 sh-1 and sh-3 compared to a control hairpin. Values are mean 6SEM.
n=3 independent experiments, ***P,.001, ns= not significant. C) Representative FACS plots showing BrdU incorporation in relation to cell cycle
stages in HMC-1.2 cells infected with control hairpin (ctr sh) compared with TET2 sh-1 and TET2 sh-3.
doi:10.1371/journal.pone.0096209.g001
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PLOS ONE | www.plosone.org 3 May 2014 | Volume 9 | Issue 5 | e96209Figure 2. Loss of Tet2 accentuates a Kit D814V driven mast cell phenotype. A) Average number of mast cells per skin section across
genotypes. N=60–80 sections from 3–4 independent animals/genotype. *P,.05. B) Average number of mast cells per stomach/esophagus section
across genotypes. N=60–80 sections from 3–4 independent animals/genotype. *P,.05. For Figure 2A and 2B, numbers 1–4 indicate the following
genotypes: 1=WT ctr, 2=Tet2
+/+;Kit D814, 3=Tet2
2/2;Kit D814, 4=Tet2
2/2;Kit WT. C) Percentage of skin sections with a defined histology score
from Tet2
+/+;Kit D814V and Tet2
2/2;Kit D814V. D) Percentage of stomach/esophagus sections with a defined histology score in Tet2
+/+;Kit D814V and
Tet2
2/2;Kit D814V animals. For Fig 2A–2D, twenty randomly chosen and independent regions of equal thickness per animal were counted in a
blinded fashion at 206magnification, and scored according to the classification reported in Table 1. Mice were all harvested between 8 and 20 weeks
after the last pI:C injection. n=4 per genotype. E) Representative pictures of Giemsa staining performed on skin (left panels) or stomach/esophagus
sections (right panels) prepared from Tet2
+/+;Kit D814V and Tet2
2/2;Kit D814V animals. Mast cells stain dark blue in these sections. Scale bar
represents 100 mm.
doi:10.1371/journal.pone.0096209.g002
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2/2;Kit D814V (n=80 from 4
independent animals/genotype, P=.03, Fig 2B). The deletion of
Tet2 alone was not sufficient to cause disease in absence of Kit
D814V (WT ctr vs Tet2
2/2; Kit WT P=.5 in the skin and P=.2,
n=60–80 sections) underscoring the role of Tet2 as a disease
modifier, rather than a disease-initiating molecular lesion.
Given that mast cell aggregates ranged in dimension from small
infiltrates to mast cell tumors, we defined a histology score
(Table 1) to classify and compare disease aggressiveness across
areas of affected genotypes. Loss of Tet2 in Kit D814V positive
animals was associated with a more aggressive disease phenotype,
as evidenced by the presence of histological sections with a score of
4 or greater in target organs (Fig. 2C–2E). These data suggest that
simultaneous expression of Kit D814V and loss of Tet2 cooperate
in the mast cell compartment and result in a more aggressive
phenotype in the skin and the digestive tract than when Kit
D814V is present alone.
SM is thought to originate from BM stem cells/progenitors that
then colonize other sites of disease [28]. The Kit D814V-MxCre
model does not develop mast cell infiltration of the BM [23].
However, because Mx-Cre induces deletion of floxed alleles in the
BM hematopoietic compartment, we wanted to assess the effect of
the Kit mutation alone and of the additional deletion of Tet2
specifically in stem/progenitor cells of the BM, which give rise to
mast cells. We therefore performed colony-forming assays and
competitive transplants, and found that deletion of Tet2 conferred
both increased replating ability to Kit D814V progenitors in vitro
and a competitive advantage to stem cell/progenitors in vivo
(Figure S2, panel A and B).
Loss of one or both copies of Tet2 increases proliferation
and impairs differentiation of BMMC carrying the Kit
D184V mutation
Next, we analyzed the interplay between these two molecular
hits during the specification of mast cells from BM progenitors.
Given that the identity of mast cell progenitors in adult mice is still
controversial [29,30], we took advantage of an established in vitro
system that leads to the generation of mature mast cells from bone
marrow (BMMCs) upon prolonged culture in the presence of IL-3
[31,32]. We compared BMMCs from mice harboring the Kit
D814V mutation, and both, one or no copies of Tet2 (Tet2
+/+;Kit
D814V, Tet2
+/2;Kit D814V and Tet2
2/2;Kit D814V) in the
hematopoietic compartment. Excision of the stop cassette allowing
expression of the Kit D814V transgene and deletion of the Tet2
floxed allele at the genomic level were verified in BMMCs by PCR
(Figure S3, panel A–C). Tet2 mRNA was appropriately reduced
according to the genotype (Fig. 3A). Loss of one or both copies of
Tet2 did not alter the constitutive phosphorylation of c-Kit caused
by the presence of the activating mutation Kit D814V in BMMCs
(Fig. 3B, lanes 2–4). BMMCs carrying one or no copies of Tet2 in
addition to the Kit D814V mutation displayed increased prolifer-
ation compared to Tet2
+/+;Kit D814V cells as measured by BrdU
incorporation (Fig. 3C) (% cells in S phase= 6.7% Tet2
+/+;Kit
D814V vs. 13.2 Tet2
+/2;Kit D814V vs. 12.8 Tet2
2/2;Kit
D814V, n=3, P=.1 for Tet2
+/2 and .01 for Tet2
2/2 compared
to Tet2
+/+;Kit D814V,).
Loss of Tet2 also impaired the differentiation of BMMCs. After
four weeks in culture with IL-3, 92% of Tet2
+/+;Kit D814V, but
only 75% of Tet2
+/2;Kit D814V and 64% of Tet2
2/2;Kit
D814V stained double positive for c-Kit and Fce (co-expression of
both markers is indicative of full maturation of mast cells) (Fig. 3D,
n=3, P=.001 for Tet2
+/2 and .02 for Tet2
2/2 compared to
Tet2
+/+;Kit D814V). The decreased number of double positive
cells upon Tet2 deletion was accompanied by a concomitant
increase in cells expressing Fce only (Figure S3, panel D).
Morphological analysis of BMMCs revealed that granule forma-
tion was reduced upon loss of Tet2 (Fig. 3E, see Tet2
+/+ in
comparison with Tet2
+/2 and Tet2
2/2;Kit D814V), suggesting a
delayed maturation stage of Kit D814V-Tet2 deleted cells
compared to their Tet2 WT counterpart. These morphological
changes did not correlate with an altered pattern of expression of a
set of mast cell-specific genes (Figure S3, panel E). Together, our
data show that loss of function of Tet2 cooperates with Kit D814V
to enhance proliferation and alter differentiation of mast cells
derived in vitro from murine bone marrow progenitors, supporting
the hypothesis that the two hits exerts their effect during the
specification of mature mast cells from uncommitted progenitors.
Effect of loss of Tet2 on Kit D814V-driven ALL initiation
and progression
As previously reported [23], we noted that Kit D814V;Mx1-Cre
transgenic animals induced with pI:C succumb to a disease that
resembles human acute lymphoblastic leukemia (ALL). In our
experiments, there was no significant difference in the incidence of
ALL upon deletion of one or both copies of Tet2 (Table S2).
White blood cell counts (WBCs) were significantly higher in
Tet2
2/2;Kit D814V leukemic mice compared with Tet2
+/+;Kit
D814V (Fig. 4A), but there was no significant difference in WBC
between Tet2
+/+;Kit D814V and Tet2
+/2;Kit D814V mice
(Fig. 4B). A trend toward higher spleen weights (a measure of
the disease burden in moribund animals) in Tet2
2/2;Kit D814V
mice correlated with higher WBC in these animals, but did not
reach statistical difference when compared to Tet2
+/+;Kit D814V
or Tet2
+/2;Kit D814V animals. There was also no difference
across genotypes in disease latency, based on the average time
after pI:C when mice were found moribund (Fig. 4C). All mice
Table 1. Histology score used to classify skin and stomach/esophagus regions from animals with mastocytosis.
Histology Score Number of mast cells Description
0 0–30 mast cells
1 31–50 mast cells Increased diffuse infiltrate
2 51–100 mast cells Mast cell accumulation
3 101–200 mast cells Mast cell tumor,500 mm
4 201–500 mast cells Mast cell tumor (500–100 mm)
5 501–1000 mast cells Mast cell tumor (1000–1500 mm)
6 .1000 mast cells Large tumor.1500 mm
doi:10.1371/journal.pone.0096209.t001
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PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e96209Figure 3. Effects of loss of Tet2 on BMMCs derived from Kit D814V-MxCre mice. A) Tet2 mRNA levels measured in BMMCs upon Mx1-Cre-
mediated deletion of Tet2. Data are presented as fold change of Tet2 mRNA/Gapdh mRNA levels relative to Tet2
+/+;Kit D814V. Data represent mean
6SEM, n=3, *P=,05, ***P,.001. B) Phosphorylation of the Kit receptor in the absence of its ligand SCF due to the presence of a Kit activating
mutation in BMMCs from Tet2
+/+;Kit D814V, Tet2
+/2;Kit D814V and Tet2
2/2;Kit D814V animals. The western blot shown is representative of two
independent experiments with similar results. Two different glycosylated forms of the Kit receptor are indicated. CG=complex glycosylation form;
HM=high-mannose form. Total levels of c-KIT and b-actin are shown as loading controls. C) Proliferation of BMMCs carrying the Kit D814V mutation
upon loss of Tet2. Data show average percentage 6SEM of BrdU-positive BMMCs across genotypes, n=3, *P,.05, ns = not significant. D)
Differentiation of Kit D814V positive BMMCs in the absence of Tet2. Data show average percentage 6SEM of double positive (Fce
+c-Kit
+) BMMCs from
Tet2
+/+;Kit D814V, Tet2
+/2;Kit D814V and Tet2
2/2;Kit D814V (64.168.2) after 4 weeks in culture with mIL-3. n=3, *P=,05, **P,.01, ns=not
significant E) Representative images of Tet2
+/+;Kit D814V,Tet2
+/2;Kit D814V and Tet2
2/2;Kit D814V BMMCs. Scale bar =20 mm. Arrows indicate cells
containing granules, which is indicative of a more differentiated phenotype.
doi:10.1371/journal.pone.0096209.g003
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cutaneous mast cells (data not shown). Leukemic blasts from all
genotypes infiltrated the bone marrow, spleen and liver of diseased
animals (Figure S4, panel A). Blast cells in the peripheral blood,
marrow and spleen expressed B220 and CD19, suggesting that the
leukemia had an immature B cell origin (Figure S4, panel B).
Sorted blast cells expressed the Kit D814V allele (Figure S4, panel
D) and displayed reduction of Tet2 expression consistent with their
genotype (Figure S4, panel C), confirming that the leukemic clone
harbored both genetic lesions. Upon transplantation into suble-
thally irradiated recipients, an equal number of blast cells from
primary Tet2
+/+;Kit D814V, Tet2
+/2;Kit D814V and Tet2
2/
2;Kit D814V mice generated ALL in secondary mice with the
same characteristics of the primary disease. There was no
difference in the penetrance of disease across the three genotypes
in recipient animals, but the median survival was slightly but
significantly reduced for recipients of the Tet2
2/2;Kit D814V
group compare with the other two genotypes (median survival for
Tet2
+/+;Kit D814V and Tet2
+/2;Kit D814V was 13 days, 11 days
for Tet2
2/2;Kit D814V; P=.009; Fig. 4D). WBC and spleen
weight were comparable across groups of secondary transplanted
recipients (Fig. 4E–F). From these data, we conclude that Tet2 is
not required for the initiation of Kit D814V-driven acute
lymphoblastic leukemia, but may play a role in disease progression
in this model.
Cooperation between the two lesions in a mast cell-
specific context
Given the high percentage of mice succumbing to ALL in our
Mx-Cre model, we hypothesized that using a mast cell-specific Cre
would obviate lymphoid leukemias and allow full penetrance of the
mast cell phenotype. Because the Mcpt5 promoter is active
selectively in mature mast cells [25], expression of the Kit D814V
allele driven by this lineage-specific Cre recombinase causes a slow
onset (9 months) mastocytosis confined to the skin [23]. In our
experiments, the average number of mast cells per skin section was
42.5 in Tet2
+/+;Kit D814V;Mcpt5-Cre, 77.3 in Tet2
+/2;Kit
D814V;Mcpt5-Cre and 56.5 in Tet2
2/2;Kit D814V;Mcpt5-Cre
(n=56–96, n=3–5 animals per genotype). Although there was a
trend towards an increased number of mast cells in the skin of
Tet2
+/2;Kit D814V;Mcpt5-Cre and Tet2
2/2;Kit D814V;Mcpt5-
Cre compared to Tet2
+/+;Kit D814V;Mcpt5-Cre, the difference
didn’t reach statistical significance (P=.1 and .2, respectively).
Importantly, the number of mast cells per skin section in Tet2
+/
2;Kit WT;Mcpt5-Cre and Tet2
2/2;Kit WT;Mcpt5-Cre was not
significantly different from the WT control group (Fig 5A),
suggesting that in the absence of the Kit D814V lesion, deletion of
Tet2 cannot initiate disease in mature mast cells. We also observed
that only Tet2
+/2;Kit D814V;Mcpt5-Cre and Tet2
2/2;Kit
D814V;Mcpt5-Cre animals had aggressive disease as assessed by
sections with histology scores .4, according to the classification
reported in Table 1 (Fig. 5B and 5C), although the severity of
disease varied considerably across skin sections from individual
mice. Thus, our data strongly suggest that the cell of origin of the
transformed and more aggressive phenotype of mast cell disease
likely is a more primitive hematopoietic progenitor and that loss of
Tet2 restricted to mature mast cells only modestly accentuates the
Kit D814V-driven mast cell skin phenotype.
Combination therapy with dasatinib and low-dose
decitabine in TET2 mutated SM
Next, we exploited the cooperation between loss of function of
TET2 and KIT D816V in the HMC-1.2 cell line to validate
possible combinatorial approaches to treatment for ASM and
MCL [8,33]. Loss of TET2 is believed to cause an aberrant
methylation of promoter regions in AML [34]. We reasoned that if
the same hypermethylator phenotype was caused by loss of TET2
in the KIT D816V-positive HMC-1.2 cell line, resulting silencing of
gene expression in these cells could potentially be reversed by
treatment with epigenetic modifiers, providing an enhanced effect
to dasatinib (DASA). We therefore pre-treated HMC-1.2 cells
transduced with a control sh or with two independent shRNAs
against TET2 with low doses (0.5 mM) of decitabine (DAC)
followed by treatment with DASA and performed Annexin V
staining. The number of apoptotic (7-AAD
2/Annexin V
+) and
dead cells (7-AAD
+/Annexin V
+) in TET2 KD cells treated with
the drug combination was higher than in TET2 KD HMC-1.2
treated with either of the drugs alone (Fig. 6A). In HMC-1.2 cells
treated with a ctr sh (TET2 WT), the drug combination induced
only a modest effect compared to the TKI alone, due to a lower
efficacy of DAC alone in TET2 WT compared to TET2 KD cells
(P=.02 and P=.03 for sh-1 and sh-3 compared to ctr sh treated
with DAC alone). Importantly, in the experiments reported here,
the number of apoptotic and dead cells was significantly higher in
TET2 sh-1 HMC-1.2 cells treated with low doses of DAC followed
by DASA than in the control sh group (P=.02). Although not
reaching statistical significance, there was also a trend towards
higher numbers of apoptotic cells in TET2 sh-3 HMC-1.2 cells
treated with the drug combination than in the control group
(P=.09). Treatment with both drugs induced cleavage of
CASPASE 3 to a larger extent in TET2 KD sh-1 and sh-3 than
in control cells (Fig. 6B, densitometric quantitation of the ratio
between cleaved CASPASE 3 and b-Actin expressed as fold
change to DMSO treated sample in each condition was: 1 vs. 19.1
in TET2 sh-1, 1 vs. 26.6 in TET2 sh-3 and 1 vs. 14.7 in ctr sh).
Furthermore, we observed that, as expected, loss of TET2 did not
appear to alter the mechanism of action of DASA, which caused
comparable inhibition of phosphorylation of its target SRC kinase
and its downstream effector STAT5 in the three conditions
(Fig. 6C). We also tested the feasibility of adding DAC to a novel
promising TKI, midostaurin (PKC412). Addition of DAC to
PKC412 caused only a modest, non-significant increase in the
percentage of dead and apoptotic cells compared to the TKI alone
(P=.07, P=.1 and P=3 for TET2 sh-1, sh-3 and ctr sh,
respectively), but the number of apoptotic and dead cells was
significantly higher in TET2 sh-1 and sh-3 HMC-1.2 cells treated
with the two drug-combination than in the control sh group
(P=.005 and P=.01, respectively)(Figure S5). Together, our data
suggest that SM with activating mutations in KIT and loss of
TET2 is more susceptible to treatment with DAC and DASA than
either compound alone, and pretreatment with DAC might also
enhance the effect of PKC412 in this setting.
Discussion
Aggressive forms of systemic mastocytosis (SM) are rare, but
difficult to treat. Identifying new molecular targets in aggressive
forms of SM may allow for a better stratification of patients and a
more effective therapeutic approach. Recent data from primary
human samples reported a high frequency of TET2 mutations in
SM and a potential role for loss of function of this gene in
modifying the disease phenotype [11,12,22]. In this study, we used
a combination of in vitro and in vivo models to investigate a role for
TET2 in the pathogenesis of KIT D816V-positive systemic
mastocytosis.
First, using a model where Kit D814V is expressed in all
hematopoietic cells and Tet2 is deleted under the control of an
Tet2 and KIT D814V in Mouse Models of Mastocytosis
PLOS ONE | www.plosone.org 7 May 2014 | Volume 9 | Issue 5 | e96209Figure 4. Tet2 deletion affects progression but not initiation of Kit D814V-driven ALL. A) Leukocyte counts in moribund leukemic animals
according to genotype. Each data point represents an individual animal. **P,.01. B) Leukemic infiltration of the spleen expressed as weight (in mg)
across genotypes. C) Latency of disease (expressed as weeks after the last pI:C injection when mice were found moribund) across genotypes. Data in
A B, C is presented as mean 6SEM (n=3–12 per group). D) Kaplan-Meier plot demonstrating survival of recipients transplanted with Tet2
+/+;Kit
D814V (black line),Tet2
+/2;Kit D814V (grey line) and Tet2
2/2;Kit D814V (black dotted line) lymphoid leukemic blasts (median survival, 13, 13 and 11
days respectively, n=10–15 per group, P=.009). E) Leukocyte counts in secondary moribund leukemic animals according to genotype. Each data
point represents an individual animal. F) Leukemic infiltration of the spleen expressed as weight (in mg) across genotypes of secondary animals. ns =
not significant.
doi:10.1371/journal.pone.0096209.g004
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PLOS ONE | www.plosone.org 8 May 2014 | Volume 9 | Issue 5 | e96209Figure 5. Expression of Kit D814V and loss of Tet2 in MC partially recapitulates the Mx1-Cre-mediated phenotype. A) Cutaneous
mastocytosis in mice expressing Kit D814V under the control of a mast cell-specific Cre (Mcpt5-Cre) promoter. Graph represents the average number
of mast cells/skin section across listed genotypes. N=56–96 from 3–4 independent animals per genotype. ns=not significant. Numbers 1–6 indicate
the following genotypes: 1=WT ctr, 2=Tet2
+/+;Kit D814;Mcpt5-Cre, 3=Tet2
+/2;Kit D814;Mcpt5-Cre, 4=Tet2
2/2;Kit D814V;Mcpt5-Cre, 5=Tet2
+/2;Kit
WT;Mcpt5-Cre,6=Tet2
2/2;Kit WT;Mcpt5-Cre, B) Histological score of disease in affected Mcpt5-Cre animals. Each skin region was scored according to
the criteria reported in Table 1. Bar graph represents the percentage of sections per genotype with a defined histology score (from 3 to .4). Mice
analyzed were 9-month-old (n=3–4 per genotype). C) Representative microphotographs showing mast cell infiltration in Tet2
+/+; Kit D814V;Mcpt5-
Cre (dermal lymph node), Tet2
+/2;Kit D814V;Mcpt5-Cre and Tet2
2/2;Kit D814V;Mcpt5-Cre animals (skin sections). Mast cells stain dark blue in these
sections. Scale=100 mm.
doi:10.1371/journal.pone.0096209.g005
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PLOS ONE | www.plosone.org 9 May 2014 | Volume 9 | Issue 5 | e96209Mx1-Cre promoter, we could conclusively demonstrate that the
two mutations cooperate at the level of hematopoietic stem and
progenitor cells in the bone marrow. This was evident in
functional assays of these cells, including in vitro CFUs assays
and in vivo competitive transplants, as wells as during the in vitro
specification of mast cells from bone marrow progenitors
(BMMCs).
In our experiments, loss of Tet2 led to increased proliferation
and a block in differentiation of KIT D814V positive BMMCs. We
found that the coexistence of Tet2 deletion and the Kit D814V
mutation was insufficient to confer IL-3 independency to BMMCs
(data not shown), suggesting that additional genetic alterations are
required for transformation of these cells in vitro, or that the
transforming requirement for these cells in vitro might differ from
those required to generate a mast cell disease in vivo.
The interplay between loss of function of Tet2 and Kit D814V
also had specific consequences on the mast cell lineage in vivo.W e
found that loss of Tet2 conferred more aggressive histological
features to the SM phenotype in KitD814V transgenic mice,
including increased mast cell accumulation in the skin and
digestive tract. This observation contributes a possible new
mechanism to the variability in clinical phenotypes of mast cell
diseases.
In our in vivo model, expression of Kit D814V and simultaneous
deletion of Tet2 in mature mast cells in the skin using the Mcpt5-
Cre driver appeared to cause a more aggressive disease phenotype,
but the difference between genotypes did not reach statistical
significance. We conclude that the two lesions together have only
modest transforming ability when expressed in the mature mast
cell compartment compared with BM stem cells/progenitors.
Therefore, data presented here validate loss of Tet2 as a molecular
event specifically associated with more aggressive types of SM,
which originate from the BM progenitor compartment and cause
infiltration of various organs. Importantly, we also demonstrate
here that the presence of Tet2 mutations alone is not sufficient to
initiate mastocytosis, nether in the bone marrow compartment,
nor in mature mast cells in the skin.
In this study, we found that all mice that succumbed to an ALL-
like malignancy demonstrated an increase in cutaneous mast cells,
suggesting that the Kit D814V transgenic model could serve as a
model for ALL associated with SM. In humans, systemic
mastocytosis with associated clonal hematological non-mast cell
Figure 6. Knock down of TET2 enhances the response of HMC-1.2 to epigenetic modifiers. A) HMC-1.2 transduced with two hairpins
against TET2 (TET2 sh-1 and TET2 sh-3) or a control shRNA (ctr sh) were treated for 72 hs with low doses of DAC (0.5 mM) or DMSO. After 72 hs, cells
were washed and resuspended in media containing DMSO or DASA at a concentration of 1 mM. Annexin V staining was performed 24 hs after the
addition of DASA. Bar graph shows percentage of apoptotic cells (Annexin V
+ 7-AAD
2) and dead cells (Annexin V
+ 7-AAD
+) for each treatment
condition. (n=3; data are expressed as mean 6SEM, *P,.05. B) Western blot showing cleavage of CASPASE 3 in HMC-1.2 with or without TET2
shRNA, treated with DAC and DASA or vehicle control. b-actin levels were used as a loading control. Numbers below the b-actin blot indicate the fold
change to untreated of the ratio between the cleaved CASPASE 3 band and the loading control, as quantified by densitometry. One of two
independent experiments with similar results is shown. C) Phosphorylation of SRC and STAT5 after treatment with DASA, with and without
pretreatment with DAC. Total SRC and total STAT5 levels were determined to confirm equal loading. One of two or three independent experiments is
shown.
doi:10.1371/journal.pone.0096209.g006
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PLOS ONE | www.plosone.org 10 May 2014 | Volume 9 | Issue 5 | e96209lineage diseases (SM-AHNMD) is a heterogeneous clinical entity
[35,36,37], with a variable presence of KIT D816V in the
malignant non-mast cell clone. Although ALL associated with
SM has been reported only in sporadic cases [38,39], the presence
of the KIT D816V mutation has been documented in lymphocytes
from patients with aggressive type of disease or MCL [5], and
previous retroviral and transgenic models have demonstrated that
Kit D814V has a preferential transforming potential on B cell
precursors [40,41].
Deletion of Tet2 did not influence initiation of Kit D814V-
driven ALL-like disease in our experiments. This may be
explained by the very short latency of the malignant disease in
our model. On the other hand, TET2 mutations have not been
reported so far in human B-ALL at diagnosis [42]. However, in
our experiments loss of both copies of Tet2 shortened survival of
secondary recipients, suggesting that loss of Tet2 plays a role in
progression of B-ALL initiated by Kit D814V. It will be interesting
to analyze a larger cohort of adult patients with B-ALL (where
samples at diagnosis and relapse are available), to examine the role
of TET2 in this disease.
DASA has partial efficacy in patients with KIT D816V positive
SM, and its tolerability profile frequently limits dose escalations in
the clinical setting [9]. DAC and 5-azacytidine (5-AZA), which are
effective for MDS and AML [43], have been shown as single agents
to induce apoptosis in a human KIT D816V positive cell line (HMC-
1.2) at high doses [44]. Recent evidence from both hematological
and solid tumors has demonstrated that treatment of malignant cell
lines with low doses of demethylating agents such as DAC and 5-
AZA induces stable epigenetic remodeling of the treated cell
genomes and induces apoptosis [45,46]. These data suggest that low
doses of these epigenetic drugs could be more effective than high
doses. We found that low doses of DAC in combination with DASA
are effective in inducing apoptosis and cell death in HMC-1.2 cells,
and that the two-drug combination is more effective upon TET2
depletion. We also provide data suggesting that the combination of
midostaurin (PKC412) and DAC works well in vitro on cell lines
carrying the Kit activating mutation D816V and loss of TET2. As
more clinical data become available on the efficacy and toxicity
profileofmidostaurinasasingleagentinthe treatmentofASM(10),
our data provide an in vitro rationale to exploit the cooperation
between this TKI and epigenetic modifiers. Additional studies are
warranted to explore how TKIs and DAC act in combination and
toinvestigatetheeffectofDAConthe epigenomeofmalignantmast
cells. We believe that our findings may lead to new approaches to
the treatment of patients with ASM harboring both KIT D816V and
mutations in TET2.
Supporting Information
Figure S1 shRNA-mediated knock down of TET2 in
HMC-1.2 A) Reduction in the level of TET2 mRNA was
quantified using qRT-PCR and normalized to the housekeeping
gene GAPDH. RNA was isolated from HMC-1.2 seven days after
transduction. TET2 sh-1 and TET2 sh-3 were used for
experiments described in the results section. Values are presented
as fold change to ctr sh and represent means 6SEM (n=3). The
Ctr sh used for this and all subsequent experiments was the
Luciferase G4 construct from Sigma-Aldrich (St. Louis, MO). B)
Histogram plot demonstrating total 5-hmC content (quantified by
intracellular flow staining) in HMC-1.2 cells upon KD of TET2.
The grey filled curve represents the secondary Ab control, solid
and dotted black lines indicate TET2 sh-1 and sh-3 and the
dashed black line represents ctr sh. Shown is one of two
independent experiments with similar results. C) Number of
HMC-1.2 cells migrated in response to hSCF in an in vitro
transwell migration assay. Bar graph represents average fold
change in number of migrated HMC-1.2 transduced with TET2
sh-1 and sh-3 relative to ctr sh (n=3, error bars represent SEM).
No significant difference was observed among experimental
groups.
(PDF)
Figure S2 BM immunophenotype and competitive
transplants in Mx1-Cre transgenic mice. A) Total number
of colonies formed in methylcellulose from Tet2
+/+;Kit D814V,
Tet2
+/2;Kit D814V and Tet2
2/2;Kit D814V animal at the initial
density (1
st round) and after a second and third round of replating.
B) Peripheral blood chimerism data on recipient animals
transplanted with equal doses of whole bone marrow test cells
(45.2) and supporting cells (45.1/45.2). Data show a significant
repopulation advantage for both Tet2
+/+;Kit D814V and Tet2
+/
2;Kit D814V at 16 and 20 weeks over competitor cells, with a
more pronounced competitive advantage for Tet2
+/2;Kit D814V
20 weeks after transplantation (*P,.05 Tet2
+/+;Kit D814V vs.
Tet2
+/2;Kit D814V 45.2 donor derived cells at 20 weeks).
(PDF)
Figure S3 Validation of pI:C-mediated deletion of the
Kit D814V flox Stop cassette and the Tet2 targeted allele
in Mx1-Cre transgenic animals. A) Schematic view of the
target allele in Kit D814V floxed animals. B) Schematic view of
the target allele in Tet2 floxed animals. C) Kit D814V Stop
deletion and Tet2 deletion PCR on genomic DNA extracted from
BMMCs from induced animals. Position and size of wt, floxed and
deleted alleles are shown. Numbers from 1 to 5 indicate the
following genotypes: 1)Mx1-Cre, 2)Tet2
+/+;Kit D814V, 3)Tet2
+/
2;Kit D814V, 4)Tet2
+/2;Kit D814V, 5)Tet2
Fl/WT;Kit D814V
Fl.
D) Percentage of BMMCs positive for Fce but negative for c-Kit
after 4 weeks in culture with IL-3. Single positive cells were
2.661.2 for the Tet2
+/+;Kit D814V, 11.2762.1 for the Tet2
+/
2;Kit D814V and 19.5769.5 for the Tet
2/2;Kit D814V
group.*P,.05. E) qRT-PCR analysis of bone-marrow specific
transcripts across genotypes. There was no significant difference in
the level of carboxypeptidase 3 (Cpa-3), Il-4 and Tnfa mRNA/
Gapdh across genotypes. Values are expressed as fold change to
Tet2
+/+;Kit D814V, and they all represent mean 6SEM (n=3).
Ns=not significant.
(PDF)
Figure S4 Characterization of the ALL phenotype in
diseased animals. A) Representative H&Estaining ofperipheral
bloodsmear,liver,spleenand bonemarrowsectionsfromadiseased
animal. Scale bars represent 25 mm and 200 mm, respectively. B)
Expression of B220 and CD19 on ALL blasts C) mRNA levels of
Tet2 normalized to Gapdh mRNA in sorted blasts (data are
expressed as fold changes relative to Tet2
+/+;Kit D814V animals
and represent means 6 SEM (n=3–4 animals/genotype)). D)
Sequence analysis of cDNA from sorted blasts to verify the presence
of the Kit D814V mutant allele in diseased animals. Data presented
in A, B, D were based on one Tet2
+/2;Kit D814V animal, but were
reproduced in multiple animals across different genotypes.
(PDF)
Figure S5 Knock-down of Tet2 enhances response of
HMC-1.2 to midostaurin and decitabine. HMC-1.2 cells
were infected with two sh targeting TET2 (sh-1 and sh-3) and a
control sh. Transduced cells were treated with decitabine or
DMSO for 72 hours, then washed and treated with midostaurin
(PKC412). Annexin V staining was performed 24 hours after
PKC412 treatment was started. Bar graph indicates percentage of
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PLOS ONE | www.plosone.org 11 May 2014 | Volume 9 | Issue 5 | e96209apoptotic (Annexin V
+/7 AAD
2) and dead cells (Annexin V
+/7
AAD
+) per treatment condition according to genotype. Pretreat-
ment of cells with decitabine did not significantly increase the
percentage of dead and apoptotic cells compared to treatment
with PKC412 alone (P=.07, P=.1 and P=.3 for TET2 sh-1,
TET2 sh-3 and ctr sh). However, the combination therapy worked
significantly better in TET2 KD than in ctr sh cells (**P,.01 for
TET2 sh-1 vs ctr sh, *P,.05 for TET2 sh-3 vs ctr sh). All values
represent mean 6SEM (n=3).
(PDF)
Table S1 Sequence of the short hairpins used to target
TET2.
(PDF)
Table S2 Incidence of ALL in primary Mx1-Cre trans-
genic mice. A cohort of 6–12 mice per genotype was observed
for 20 weeks after the last pI:C injection, and the number of mice
with ALL was recorded. There was no significant difference in the
incidence of ALL across genotypes.
(PDF)
Methods S1 Supporting methods and references.
(PDF)
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